Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
As patients struggle with treatment burdens and suboptimal outcomes, new pipeline therapies spark hope for meaningful transformation across nAMD, DME, GA, and UME. Exton, PA, August 28, 2025 — In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S. ophthalmologists,
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. Exton, PA, August 28, 2025 – The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a
New patient chart audit uncovers rising wave of patient-driven treatment switches in ulcerative colitis and Crohn’s disease, opening the door for brands to accelerate market share gains. Exton, PA, August 26, 2025 – Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever
TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity. EXTON, PA, August 25, 2025 – According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar
Breakthrough therapies targeting APOL1 and reducing steroid dependence could redefine treatment standards for FSGS EXTON, PA, August 21, 2025 —The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection point. New data from Spherix Global Insights’ seventh annual Market Dynamix™:
EXTON, PA, August 19, 2025 – Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical stakeholders with critical, forward-looking intelligence into payer priorities, strategies, and evolving access dynamics across a broad range of therapeutic categories. The report will be delivered to
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics’ Casgevy holding a competitive edge over bluebird bio’s Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, August 14, 2025 — As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON, PA, August 7, 2025 – Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), and
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights. Exton, PA, August 6, 2025 – The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, August 6, 2025 — According to the latest findings from Spherix Global Insights’
Hematologists are poised to jump on new market entrants once available, as high unmet need and frustration with current treatment standards persist in w-AIHA. EXTON, PA, July 29, 2025— According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune hemolytic anemia (w-AIHA)
Doctors, patients struggle with new drug coverage. The recent approval of a new drug to treat psoriatic arthritis (PsA) was a welcome development for people living with this painful condition and the doctors who treat them. But those enthusiastic to try Bimzelx (bimekizumab) have run into a common problem associated
Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies with steroid-sparing potential and easier administration EXTON, PA, July 23, 2025 — Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40%
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Exton, PA, July 17, 2025 – The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as well as continued use of Alexion’s Soliris and Ultomiris and Apellis’ Empaveli. EXTON, PA, July 17, 2025 – In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements. Spherix Global Insights released data that examine the competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
